# A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis

> **NCT02035553** · PHASE2 · COMPLETED · sponsor: **ACADIA Pharmaceuticals Inc.** · enrollment: 181 (actual)

## Conditions studied

- Alzheimer's Disease Psychosis

## Interventions

- **DRUG:** Pimavanserin tartrate
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02035553
- **Lead sponsor:** ACADIA Pharmaceuticals Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-11
- **Primary completion:** 2016-09-28
- **Final completion:** 2016-10-27
- **Target enrollment:** 181 (ACTUAL)
- **Last updated:** 2017-10-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02035553

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02035553, "A Study of the Safety and Efficacy of Pimavanserin in Patients With Alzheimer's Disease Psychosis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02035553. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*